Urolithin A and Mitophagy: Promising Mitochondrial Science or Expensive Longevity Marketing?

Urolithin A has become one of the more heavily promoted compounds in mitochondrial and longevity medicine. Supplement companies describe it as a way to renew aging mitochondria, restore cellular energy, improve muscle strength, and address aging closer to its source.

Unlike many longevity ingredients built almost entirely on animal research, urolithin A does have randomized human trials behind it. That makes it worthy of attention. It does not, however, make every claim appearing on a supplement landing page clinically established.

The honest answer is that urolithin A represents promising mitochondrial science wrapped in marketing that frequently gets ahead of the evidence. It may have a useful role for selected people, particularly older adults concerned about declining muscle function, but it should not be confused with proven age reversal or treated as a replacement for exercise, adequate protein, sleep, metabolic health, or appropriate medical evaluation.

What Is Urolithin A?

Urolithin A is a postbiotic metabolite produced when certain gut bacteria process ellagitannins and ellagic acid found in foods such as pomegranates, walnuts, and some berries.

Not everyone produces meaningful amounts. Differences in gut microbial composition help explain why two people can eat the same food yet generate very different urolithin A levels. Direct supplementation bypasses some of that variability by delivering a standardized dose.

Its primary scientific interest involves mitophagy, a form of cellular quality control that identifies and removes damaged or dysfunctional mitochondria. This matters because mitochondria generate much of the energy used by cells, and mitochondrial quality control tends to become less efficient with age.

The mechanism is plausible. The larger question is whether altering that mechanism produces meaningful improvements in strength, mobility, healthspan, disease risk, or longevity.

Mitophagy is only one part of mitochondrial quality control. Healthy mitochondria depend on a coordinated balance between removing damaged mitochondria and producing, repairing, fusing, and dividing mitochondria as cellular needs change. More mitophagy is not automatically better. Regular exercise remains the most defensible way to support this broader cycle of mitochondrial turnover and renewal. Urolithin A may provide an additional signal, but it cannot replace exercise, adequate protein, sleep, recovery, and metabolic health.

What Human Trials Have Found

Early human studies suggest that supplemental urolithin A is absorbed, is generally well tolerated over the periods studied, and can influence molecular pathways associated with mitochondrial function.

A 2022 randomized trial in middle-aged adults reported improvements in selected measures of leg-muscle strength and exercise performance after four months of supplementation with 500 or 1,000 mg daily. The study also reported changes in proteins and gene-expression patterns associated with mitochondrial health.

Another randomized trial, published in JAMA Network Open, studied adults between 65 and 90 years of age who received 1,000 mg daily for four months. Urolithin A improved certain secondary measures of muscle endurance. However, the primary outcomes—six-minute walking distance and maximal ATP production in hand muscle—were not significantly better than placebo.

A 2025 randomized trial of 50 healthy middle-aged adults found that 1,000 mg daily for four weeks altered several immune-cell populations and measures of immune-cell metabolism. These findings are scientifically interesting, but the study did not establish that participants experienced fewer infections, less chronic disease, slower aging, or longer life.

Overall, the human evidence supports biological activity and a possible effect on selected aspects of muscle performance. It does not yet demonstrate broad clinical rejuvenation.

Where the Marketing Moves Ahead of the Evidence

The Funding Question Matters

Many of the central human studies were funded by Amazentis, the company behind the proprietary Mitopure® ingredient used by Timeline. Several study authors have been company employees, executives, consultants, or inventors associated with relevant patents.

Commercial funding does not automatically make a study unreliable. Pharmaceutical, device, and nutritional research frequently depends on industry support. The study design, prespecified outcomes, statistical analysis, transparency, and independent replication are more informative than funding alone.

Still, when one company develops the ingredient, funds much of the research, employs several investigators, owns the patents, and markets the resulting product, the findings should be interpreted with appropriate restraint. Larger independent trials would increase confidence considerably.

Is Urolithin A Better Than Creatine?

This is not a direct either-or comparison because the compounds work differently. Creatine supports rapid energy availability within muscle and has decades of independent research involving strength, lean mass, exercise performance, and aspects of healthy aging. Urolithin A is primarily being studied as a mitochondrial quality-control intervention.

For most adults choosing where to spend limited time and money, resistance training, adequate dietary protein, creatine, sleep, and correction of nutritional or hormonal deficiencies have a stronger practical foundation. Urolithin A may be considered after those fundamentals are addressed, particularly when there is a specific concern about age-related muscle decline.

It should also not be portrayed as universally superior to CoQ10, creatine, nicotinamide riboside, NMN, or spermidine. These compounds have different mechanisms, different clinical questions, and very different levels of evidence. A comparison table that gives one branded ingredient every checkmark while reducing competing compounds to “partial” or “limited” is advertising, not a meaningful clinical comparison.

Who Might Reasonably Consider It?

Urolithin A may be reasonable to discuss for an older adult experiencing declining muscle endurance, someone unable to produce adequate urolithin A from dietary precursors, or a person who has already addressed exercise, protein intake, sleep, and metabolic health and wants to explore an additional mitochondrial intervention.

The commonly studied dose has ranged from 500 to 1,000 mg daily. Importantly, some of the stronger mechanistic and endurance findings used 1,000 mg, while many consumer products emphasize a 500 mg daily serving. Benefits observed at one dose should not automatically be assigned to another dose or formulation.

Pregnant or breastfeeding individuals, people receiving cancer treatment, and those managing significant medical conditions should discuss supplementation with their treating clinician. Evidence concerning long-term use, medication interactions, and hard clinical outcomes remains limited.

What Urolithin A Has Not Been Proven to Do

• Reverse biological aging
• Extend human lifespan
• Prevent cardiovascular disease, dementia, cancer, or frailty
• Produce meaningful fat loss or muscle growth by itself
• Replace resistance training or adequate protein
• Reliably improve fatigue or subjective energy
• Rejuvenate the entire immune system

Changes in a biomarker can help explain a mechanism. They do not automatically establish that someone feels better, functions better, avoids disease, or lives longer.

The HormoneSynergy® Perspective

Urolithin A is not another imaginary longevity molecule supported only by a mouse study and an influencer. The mechanism is credible, human trials exist, and the early findings deserve continued research.

But promising science should be described as promising science. Terms such as “mitochondrial renewal,” “cellular rejuvenation,” and “targeting aging at its source” create an impression of proven clinical transformation that current trials cannot support.

At approximately $74 to $99 per month for some branded products, cost also matters. A supplement may be biologically active and still offer limited practical value compared with resistance training, sufficient protein, creatine, treatment of insulin resistance, appropriate hormone evaluation, and objective monitoring of strength and body composition.

In longevity medicine, novelty should not outrank evidence. Urolithin A may eventually become a useful part of a well-designed muscle and mitochondrial health strategy. For now, it belongs in the category of credible but still developing—not proven age reversal in a gummy.

Related HormoneSynergy® Resources

• DEXA Bone Density, Body Composition and Visceral Fat Analysis
• Bioidentical Hormone and Testosterone Therapy
• Medically Supervised GLP-1 Weight Loss for Longevity™

Selected References

• Andreux PA, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism. 2019.
• Singh A, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Reports Medicine. 2022.
• Liu S, et al. Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults. JAMA Network Open. 2022.
• Denk D, et al. Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Nature Aging. 2025.

Frequently Asked Questions

Does urolithin A reverse aging?

No. It may affect mitophagy and mitochondrial biomarkers, but no human trial has shown that urolithin A reverses aging or extends lifespan.

Can urolithin A replace exercise?

No. Some effects have been observed without a structured exercise program, but urolithin A has not been shown to reproduce the broad muscular, metabolic, cardiovascular, skeletal, and cognitive benefits of exercise.

Is urolithin A worth the cost?

That depends on the individual. For most people, resistance training, adequate protein, sleep, metabolic health, and creatine should take priority. Urolithin A may be a reasonable adjunct after those foundations are addressed.

What dose has been studied?

Human trials have commonly evaluated 500 or 1,000 mg daily. Some findings highlighted in consumer advertising came from studies using 1,000 mg, so outcomes cannot automatically be transferred to every 500 mg product.

Is Mitopure® different from urolithin A?

Mitopure® is a proprietary, standardized urolithin A ingredient developed by Amazentis and sold through Timeline and other products. Evidence involving Mitopure should not automatically be applied to products with uncertain identity, purity, dosage, or stability.

Editorial Transparency: HormoneSynergy® has no financial relationship with Timeline or Amazentis and did not receive compensation for this article. This review distinguishes mechanistic findings, biomarkers, functional outcomes, and unproven longevity claims. It is educational and is not a substitute for individualized medical care.